Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ondansetron + methylphenidate
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ond-PR1 + MPh-IR is an investigational combination therapy being developed by Tong Lee at Duke University for the treatment of psychostimulant use disorder. The treatment consists of a novel pulsatile-release formulation of ondansetron (Ond-PR1) and an immediate-release formulation of methylphenidate (MPh-IR). The therapeutic rationale is based on the reactivation and reconsolidation blockade of the neural circuits involved in drug abuse. Methylphenidate, a dopamine reuptake inhibitor, is used to reactivate the consolidated dysfunctional circuit, while the delayed delivery of ondansetron, a 5-HT3 receptor antagonist, is intended to block the reconsolidation of that circuit. The pulsatile-release formulation of ondansetron was specifically designed to achieve delayed absorption in the gastrointestinal tract, ensuring the optimal timing of the two active ingredients to disrupt the addiction cycle.
- Other names
- Ond-PR1 + MPh-IR
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)AcetylcholinesteraseButyrylcholinesteraseDAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on ondansetron + methylphenidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ondansetron + methylphenidate.